Please login to the form below

Not currently logged in
Email:
Password:

BioXcel Therapeutics

This page shows the latest BioXcel Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

BioXcel Therapeutics has announced that the first patient involved in the phase 3 TRANQUILITY 2 study of BXCL501 has received a dose for the acute treatment of agitation in patients with ... Dr Robert Risinger, chief medical officer of BioXcel

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....